KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Shares Outstanding for 16 consecutive years, with $117.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 4.35% to $117.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $117.8 million, a 4.35% decrease, with the full-year FY2025 number at $117.8 million, down 4.35% from a year prior.
  • Shares Outstanding was $117.8 million for Q4 2025 at Halozyme Therapeutics, roughly flat from $117.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $143.4 million in Q1 2021 to a low of $117.5 million in Q3 2025.
  • A 5-year average of $130.6 million and a median of $131.8 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: increased 5.92% in 2021, then fell 7.6% in 2025.
  • Halozyme Therapeutics' Shares Outstanding stood at $137.5 million in 2021, then fell by 1.7% to $135.2 million in 2022, then dropped by 6.2% to $126.8 million in 2023, then dropped by 2.87% to $123.1 million in 2024, then dropped by 4.35% to $117.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Shares Outstanding are $117.8 million (Q4 2025), $117.5 million (Q3 2025), and $117.6 million (Q2 2025).